Novo Rebrands Diabetes Pill as Ozempic to Tap Blockbuster Name, Bloomberg Reports

Tiger Newspress05-01

Novo Nordisk is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the brand recognition of one of the world’s best-selling drugs, Bloomberg reported.

The Danish drugmaker will start selling Ozempic pills in doses of 1.5 milligram, 4 mg and 9 mg to adults from Monday through more than 70,000 pharmacies across the US, according to a statement Friday.

Novo Nordisk shares rose 2.8% in premarket trading.

Novo said the relaunched Ozempic pills are as safe and effective as tablets sold under the name Rybelsus, which have the same main ingredient, semaglutide, but in a different formulation and set of doses. Rybelsus will continue to be marketed outside the US.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106719343?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106719343","market":"us","top_or_hot":-1,"title":"Novo Rebrands Diabetes Pill as Ozempic to Tap Blockbuster Name, Bloomberg Reports","media":"Tiger Newspress","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the brand recognition of one of the world’s best-selling drugs, Bloomberg reported.</p><p style=\"text-align: start;\">The Danish drugmaker will start selling Ozempic pills in doses of 1.5 milligram, 4 mg and 9 mg to adults from Monday through more than 70,000 pharmacies across the US, according to a statement Friday.</p><p>Novo Nordisk shares rose 2.8% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/93dfc4607e45df9f53a57c66efa008da\" tg-width=\"538\" tg-height=\"159\"/></p><p style=\"text-align: start;\">Novo said the relaunched Ozempic pills are as safe and effective as tablets sold under the name Rybelsus, which have the same main ingredient, semaglutide, but in a different formulation and set of doses. Rybelsus will continue to be marketed outside the US.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Rebrands Diabetes Pill as Ozempic to Tap Blockbuster Name, Bloomberg Reports</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Rebrands Diabetes Pill as Ozempic to Tap Blockbuster Name, Bloomberg Reports\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2026-05-01 20:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the brand recognition of one of the world’s best-selling drugs, Bloomberg reported.</p><p style=\"text-align: start;\">The Danish drugmaker will start selling Ozempic pills in doses of 1.5 milligram, 4 mg and 9 mg to adults from Monday through more than 70,000 pharmacies across the US, according to a statement Friday.</p><p>Novo Nordisk shares rose 2.8% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/93dfc4607e45df9f53a57c66efa008da\" tg-width=\"538\" tg-height=\"159\"/></p><p style=\"text-align: start;\">Novo said the relaunched Ozempic pills are as safe and effective as tablets sold under the name Rybelsus, which have the same main ingredient, semaglutide, but in a different formulation and set of doses. Rybelsus will continue to be marketed outside the US.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVOH","symbol_name":"Novo Nordisk A/S B Shares ADRhedged","start_time":0,"source_url":"","article_id":"1106719343","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106719343","pubTimestamp":1777637787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"$Novo Nordisk(NVO)$ is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the brand recognition of one of the world’s best-selling drugs, Bloomberg...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVOH":"Novo Nordisk A/S B Shares ADRhedged","NVO":"诺和诺德","NVOX":"2倍做多NVO ETF-Defiance"},"translate_title":"据彭博社报道，Novo将糖尿病药物更名为Ozempic，以使用重磅炸弹名称","themeId":"9ec680a2539a9ae8f051490080e2eee7","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/2021891a4275baa52228c23b95baf67d","symbols_score_info":{"NVOX":0.6,"NVO":2,"NVOH":0.6},"content_text":"Novo Nordisk is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the brand recognition of one of the world’s best-selling drugs, Bloomberg reported.The Danish drugmaker will start selling Ozempic pills in doses of 1.5 milligram, 4 mg and 9 mg to adults from Monday through more than 70,000 pharmacies across the US, according to a statement Friday.Novo Nordisk shares rose 2.8% in premarket trading.Novo said the relaunched Ozempic pills are as safe and effective as tablets sold under the name Rybelsus, which have the same main ingredient, semaglutide, but in a different formulation and set of doses. Rybelsus will continue to be marketed outside the US.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106719343","isCrawlerRequest":true}